Yeomans Consulting Group Inc. Invests $295,000 in Gilead Sciences, Inc. (NASDAQ:GILD)

Yeomans Consulting Group Inc. purchased a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 2,633 shares of the biopharmaceutical company’s stock, valued at approximately $295,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. Commerzbank Aktiengesellschaft FI grew its stake in Gilead Sciences by 27.4% in the first quarter. Commerzbank Aktiengesellschaft FI now owns 13,326 shares of the biopharmaceutical company’s stock valued at $1,493,000 after purchasing an additional 2,863 shares during the last quarter. Kingsview Wealth Management LLC boosted its stake in Gilead Sciences by 2.9% during the first quarter. Kingsview Wealth Management LLC now owns 43,251 shares of the biopharmaceutical company’s stock worth $4,846,000 after buying an additional 1,237 shares during the last quarter. Graypoint LLC lifted its stake in shares of Gilead Sciences by 8.6% in the 1st quarter. Graypoint LLC now owns 12,156 shares of the biopharmaceutical company’s stock valued at $1,362,000 after purchasing an additional 965 shares during the last quarter. Mayflower Financial Advisors LLC raised its holdings in shares of Gilead Sciences by 7.3% in the 1st quarter. Mayflower Financial Advisors LLC now owns 3,676 shares of the biopharmaceutical company’s stock valued at $412,000 after buying an additional 249 shares during the period. Finally, Triasima Portfolio Management inc. purchased a new stake in Gilead Sciences during the 1st quarter worth about $414,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Price Performance

Shares of GILD traded up $0.96 during mid-day trading on Friday, hitting $109.76. 968,489 shares of the company were exchanged, compared to its average volume of 7,644,462. The stock has a market cap of $136.53 billion, a price-to-earnings ratio of 23.12, a price-to-earnings-growth ratio of 0.71 and a beta of 0.29. The company has a debt-to-equity ratio of 1.16, a quick ratio of 1.23 and a current ratio of 1.37. Gilead Sciences, Inc. has a 1-year low of $70.78 and a 1-year high of $119.96. The company has a 50 day moving average of $108.58 and a 200-day moving average of $105.06.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, beating the consensus estimate of $1.77 by $0.04. Gilead Sciences had a net margin of 20.76% and a return on equity of 51.93%. The business had revenue of $6.67 billion during the quarter, compared to analysts’ expectations of $6.77 billion. During the same quarter in the prior year, the company posted ($1.32) EPS. The business’s revenue for the quarter was down .3% on a year-over-year basis. Analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, June 27th. Shareholders of record on Friday, June 13th were given a $0.79 dividend. The ex-dividend date of this dividend was Friday, June 13th. This represents a $3.16 annualized dividend and a yield of 2.88%. Gilead Sciences’s dividend payout ratio is presently 66.53%.

Analysts Set New Price Targets

A number of research firms have weighed in on GILD. Cantor Fitzgerald started coverage on Gilead Sciences in a research report on Tuesday, April 22nd. They set an “overweight” rating and a $125.00 price objective for the company. Oppenheimer reduced their target price on Gilead Sciences from $132.00 to $125.00 and set an “outperform” rating on the stock in a report on Friday, April 25th. Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a research note on Wednesday, May 21st. Morgan Stanley boosted their price objective on Gilead Sciences from $130.00 to $135.00 and gave the company an “overweight” rating in a report on Friday, April 25th. Finally, JPMorgan Chase & Co. boosted their price objective on Gilead Sciences from $120.00 to $130.00 and gave the stock an “overweight” rating in a research report on Thursday, March 27th. Nine analysts have rated the stock with a hold rating, fourteen have issued a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $111.38.

Insider Activity

In related news, Director Jeffrey Bluestone sold 5,000 shares of Gilead Sciences stock in a transaction on Monday, July 14th. The shares were sold at an average price of $109.74, for a total transaction of $548,700.00. Following the sale, the director directly owned 8,920 shares in the company, valued at $978,880.80. This trade represents a 35.92% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction on Tuesday, July 15th. The shares were sold at an average price of $111.03, for a total transaction of $277,575.00. Following the completion of the transaction, the chief financial officer owned 162,610 shares in the company, valued at approximately $18,054,588.30. This represents a 1.51% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 72,000 shares of company stock valued at $7,844,775 over the last quarter. Company insiders own 0.27% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.